We are live on ! Find out more
ACET icon

Adicet Bio

49 hedge funds and large institutions have $56.6M invested in Adicet Bio in 2025 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 21 increasing their positions, 8 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

367% more call options, than puts

Call options by funds: $14K | Put options by funds: $3K

163% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 8

36% more capital invested

Capital invested by funds: $41.6M → $56.6M (+$14.9M)

0.53% more ownership

Funds ownership: 3.86%4.39% (+0.53%)

9% less funds holding

Funds holding: 5449 (-5)

25% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 20

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
49
Holders Change
-5
Holders Change %
-9.26%
% of All Funds
0.6%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
15
Increased
21
Reduced
8
Closed
20
Calls
$14K
Puts
$3K
Net Calls
+$11K
Net Calls Change
+$10K
Name Holding Trade Value Shares
Change
Change in
Stake
O
1
OrbiMed
New York
$8.66M +$3.45M +312,498 +44%
RCM
2
RA Capital Management
Massachusetts
$7.98M +$5.27M +476,936 +101%
Franklin Resources
3
Franklin Resources
California
$5.28M +$6.93M +626,571 New
WP
4
Woodline Partners
California
$5.26M +$6.91M +625,000 New
Vanguard Group
5
Vanguard Group
Pennsylvania
$2.45M +$959K +86,744 +42%
Adage Capital Partners
6
Adage Capital Partners
Massachusetts
$2.31M +$3.03M +274,375 New
PM
7
Prosight Management
Texas
$2.11M +$2.77M +250,244 New
Renaissance Technologies
8
Renaissance Technologies
New York
$2.05M +$1.42M +128,636 +113%
Goldman Sachs
9
Goldman Sachs
New York
$1.97M +$376 +34 +0%
SCM
10
Stonepine Capital Management
Oregon
$1.85M +$2.43M +220,011 New
Alyeska Investment Group
11
Alyeska Investment Group
Illinois
$1.72M +$1.8M +162,820 +397%
CG
12
Carlyle Group
District of Columbia
$1.54M
Acadian Asset Management
13
Acadian Asset Management
Massachusetts
$1.52M +$440K +39,802 +28%
NCM
14
NEXTBio Capital Management
California
$1.33M +$1.74M +157,827 New
Two Sigma Investments
15
Two Sigma Investments
New York
$1.22M +$1.01M +91,385 +171%
ACM
16
ADAR1 Capital Management
Texas
$1.08M +$1.42M +128,646 New
Two Sigma Advisers
17
Two Sigma Advisers
New York
$937K +$691K +62,525 +128%
Citadel Advisors
18
Citadel Advisors
Florida
$908K +$788K +71,317 +195%
DCM
19
DAFNA Capital Management
California
$790K +$1.04M +93,812 New
Geode Capital Management
20
Geode Capital Management
Massachusetts
$748K +$494K +44,710 +101%
BGM
21
Burkehill Global Management
New York
$526K +$691K +62,500 New
RP
22
Regeneron Pharmaceuticals
New York
$510K
LM
23
Luminus Management
Texas
$501K +$658K +59,558 New
BCM
24
Bridgeway Capital Management
Texas
$474K
Squarepoint
25
Squarepoint
New York
$469K +$584K +52,821 +1,820%

ACET Hedge Fund Activity: Q4 2025 in Review

49 of the 8,225 institutional investors tracked by Wall St. Rank reported a position in Adicet Bio (ACET) for Q4 2025, worth a combined $56.6M — up 36% from $41.6M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of ACET and 15 opened new positions — a net loss of 5 holders — while 8 trimmed existing stakes and 21 added.

The largest buyer was Franklin Resources, opening a new position worth an estimated $6.93M. The largest seller was Tang Capital Management, cutting an estimated $5.61M.

  • 49 institutional investors held Adicet Bio (ACET) as of Q4 2025, down from 54 in Q3 2025.
  • Funds reported $56.6M of Adicet Bio stock for Q4 2025, up 36% quarter-over-quarter.
  • 15 funds opened new Adicet Bio positions in Q4 2025 and 20 closed out, a net change of -5 holders.
  • The largest Adicet Bio buyer in Q4 2025 was Franklin Resources, an estimated $6.93M added.
  • The largest Adicet Bio seller in Q4 2025 was Tang Capital Management, an estimated $5.61M sold.

Based on aggregated 13F filings for Q4 2025.